Similar to Huntington's disease, downregulation of the mutant transcript is regarded as a promising treatment strategy for SCA3, as the ATXN3 transcript is the most upstream target in the pathological cascade underlying the disease [13,65]. This evidence concerns the gene ATXN3 and juvenile Huntington disease.